Sign inJoin free

Watch / Stock Selection

Why Stuart sees CAR Group accelerating

3 July 20266:45

Why Stuart sees CAR Group accelerating

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Key points:

  • Roberts views Carsales.com (ASX:CAR) as an AI-resilient, capital-light marketplace poised for a rebound

  • Ongoing heavy software and AI investment is seen as critical to Carsales’ global growth strategy

  • Neuren Pharmaceuticals (ASX:NEU) is regarded as a potential future ASX top 50 stock driven by its RET syndrome drug and pipeline

Stuart Roberts from Stocks Down Under sets out a bullish case for Carsales.com (ASX:CAR), arguing that established digital marketplaces with deep proprietary data are well placed against emerging artificial intelligence challengers. Roberts points to Carsales’ investment of around $120 million in software and AI tools, including a São Paulo-based team developing “genetic agents” that could handle virtual car inspections and price negotiations, as evidence of a proactive strategy to defend and grow its market position.

Roberts highlights Carsales’ half-year performance, noting revenue growth of about 8%, EBITDA above $300 million, and strong free cash flow after investment, which he says enables the group to stay on the offensive. He describes the business model as capital-light, supported by premium dealer listings and highly sticky subscriptions. Brands such as Trader Interactive in the US and platforms across South Korea, Brazil and Chile are viewed by Roberts as a scalable, global template.

Positioning Carsales as one of the “dogs of the ASX 200” set to rebound, Roberts frames the recent share price weakness as AI-driven fear rather than fundamentals. He contrasts Carsales’ ongoing software investment with Xero (ASX:XRO), which he claims is underinvesting in its platform. Roberts is also upbeat on Neuren Pharmaceuticals (ASX:NEU), citing European regulatory progress for its RET syndrome treatment and a fully owned pipeline that he contends could eventually propel Neuren into the ASX top 50.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy